FDA Approves Evoke’s Gimoti Nasal Spray

Evoke Pharma said the FDA approved the New Drug Application for Gimoti nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

• The FDA approval of Gimoti allows Evoke to access its existing $5 million line of credit from Eversana to support manufacturing and other aspects of Gimoti’s commercialization

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2020 Bloomberg L.P. All rights reserved. Used with permission.